Flow(TM) Voiding Prosthesis, following the Centers for Medicare & Medicaid Services (CMS) decision to establish national pricing for the CPT(R) codes related to physician procedures for the device.
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.
"I was sitting at home reading a book at 11 p.m. when I suddenly felt discomfort, nausea, and pain." Kim Sangwook (55), ...
The practice of routinely maintaining PIVC access has not only benefits but also risks. It’s due for a mindset shift, with ...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, introduces the PureWick™ ...
1don MSN
'Indicator of something serious': Patients warned to keep a close eye on the colour of their pee
A leading pharmacist has urged patients to keep a close eye on the colour of their urine, which can provide vital clues to ...
The global urodynamic equipment and consumables market size is expected to hit nearly USD 808.16 million by 2034, increasing ...
Documentation of any spinal cord injury diagnosis is sufficient to establish Medicare coverage for sterile catheter kits (A4297 and A4353) starting Jan. 1, according to a new local coverage determinat ...
The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback